Drugs / ravuconazole
ravuconazole
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00064311 | Jun 2003 → Sep 2004 | breast cancer, gestational trophoblastic neoplasm, infectious disease, leukemia +7 | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ravuconazole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00064311 ↗ |
| Known as | BMS-207147 | ChEMBL registry synonym — accepted as the source's own label CHEMBL294029 ↗ |
| Known as | ER-30346 | ChEMBL registry synonym — accepted as the source's own label CHEMBL294029 ↗ |
| Known as | Ravuconazol | ChEMBL registry synonym — accepted as the source's own label CHEMBL294029 ↗ |
| Modality | Small molecule | — CHEMBL294029 ↗ |
| Route | Oral | “Patients receive oral ravuconazole once daily beginning within 48 hours of the chemotherapy preparative regimen and before the initiation of cyclosporine.” NCT00064311 ↗ |